# Hoffmann-La Roche: Phase 3 study closed enrollment, 342 enrolled (Hepatocellular Carcinoma)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma |
| NCT ID | NCT04712643 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Hepatocellular Carcinoma |
| Intervention types | drug, device |
| Target enrollment | 342 |
| Site countries | China, Japan |
| Posted | 2021-01-15 |
| Planned start | 2021-03-12 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-26 |
| Last update posted | 2026-10-26 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 342 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04712643). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.